|Articles|August 9, 2021
- Pharmaceutical Executive-08-01-2021
- Volume 41
- Issue 8
Pharmaceutical Executive, August 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
Why the Pandemic is Rewriting the Biopharma Rule Bookalmost 5 years ago
Primary Care in Crisis: PCP Navigation in a Specialty Worldalmost 5 years ago
A Brave New World: Optimizing Access in Wake of COVIDalmost 5 years ago
By Any Genes Necessary: The Role of MEAs for Gene Therapiesalmost 5 years ago
A Framework for Future: Strengthening Market Access Competenciesalmost 5 years ago
Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharmaalmost 5 years ago
A Global Vision for Accessalmost 5 years ago
Early Payer-Related Lessons for Pharma Post-Aduhelm Approvalalmost 5 years ago
Biotech Capital Markets Continue to UnderperformAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
2
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
3
Pharmaceutical Executive Daily: FDA Approves Simtriyo
4
Where the True Bottlenecks Exist at FDA for Clinical Trials
5